JP2022541459A5 - - Google Patents
Info
- Publication number
- JP2022541459A5 JP2022541459A5 JP2022502422A JP2022502422A JP2022541459A5 JP 2022541459 A5 JP2022541459 A5 JP 2022541459A5 JP 2022502422 A JP2022502422 A JP 2022502422A JP 2022502422 A JP2022502422 A JP 2022502422A JP 2022541459 A5 JP2022541459 A5 JP 2022541459A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide according
- subject
- conjugated polypeptide
- soluble
- sequence numbers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962874724P | 2019-07-16 | 2019-07-16 | |
| US62/874,724 | 2019-07-16 | ||
| PCT/US2020/042161 WO2021011673A2 (en) | 2019-07-16 | 2020-07-15 | Neutralizing anti-amyloid beta antibodies for the treatment of alzheimer's disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022541459A JP2022541459A (ja) | 2022-09-26 |
| JP2022541459A5 true JP2022541459A5 (enExample) | 2023-07-24 |
| JP7685985B2 JP7685985B2 (ja) | 2025-05-30 |
Family
ID=71895293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022502422A Active JP7685985B2 (ja) | 2019-07-16 | 2020-07-15 | アルツハイマー病の処置のための中和抗アミロイドベータ抗体 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP3999532A2 (enExample) |
| JP (1) | JP7685985B2 (enExample) |
| KR (1) | KR20220034857A (enExample) |
| CN (3) | CN121800915A (enExample) |
| CA (1) | CA3147239A1 (enExample) |
| WO (1) | WO2021011673A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3658172A4 (en) | 2017-07-25 | 2021-05-05 | TrueBinding, Inc. | TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND |
| CN113711036B (zh) | 2019-01-30 | 2025-03-18 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| CN116157151A (zh) | 2020-05-26 | 2023-05-23 | 真和制药有限公司 | 通过阻断半乳凝素-3治疗炎性疾病的方法 |
| WO2026082154A1 (en) * | 2024-10-18 | 2026-04-23 | Lepu Biopharma Co., Ltd. | Anti-beta amyloid antibodies and uses thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| WO1994009817A1 (en) | 1992-11-04 | 1994-05-11 | City Of Hope | Novel antibody construct |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| WO1996033761A1 (en) | 1995-04-28 | 1996-10-31 | Medtronic, Inc. | Intraparenchymal infusion catheter system |
| WO1997014719A1 (en) | 1995-10-16 | 1997-04-24 | Unilever N.V. | A bifunctional or bivalent antibody fragment analogue |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| US5735814A (en) | 1996-04-30 | 1998-04-07 | Medtronic, Inc. | Techniques of treating neurodegenerative disorders by brain infusion |
| US20030068316A1 (en) * | 1997-02-05 | 2003-04-10 | Klein William L. | Anti-ADDL antibodies and uses thereof |
| DK0979281T3 (da) | 1997-05-02 | 2005-11-21 | Genentech Inc | Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele |
| WO2002002781A1 (en) | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
| EP1545582A4 (en) * | 2002-10-01 | 2008-09-17 | Univ Northwestern | DIFFUSIBLE DERIVATIVES DERIVED FROM AMYLOID BETA (ADDL), ADDL SUBSTITUTE, ADDL BINDING MOLECULES, AND USES THEREOF |
| US20160213794A1 (en) * | 2002-10-01 | 2016-07-28 | Northwestern University | Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules and uses thereof |
| CN1871259A (zh) | 2003-08-22 | 2006-11-29 | 比奥根艾迪克Ma公司 | 具有改变的效应物功能的经改进的抗体和制备它的方法 |
| CN101198698B (zh) | 2005-03-31 | 2014-03-19 | 中外制药株式会社 | 通过调节多肽缔合制备多肽的方法 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| PE20090329A1 (es) * | 2007-05-30 | 2009-03-27 | Abbott Lab | Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos |
| DK2170389T3 (en) * | 2007-06-12 | 2015-01-19 | Ac Immune Sa | Humanized antibodies against amyloid beta |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| US9272030B2 (en) * | 2007-10-17 | 2016-03-01 | Janssen Sciences Ireland Uc | Use of tau to monitor immunotherapy |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| WO2010054007A1 (en) * | 2008-11-07 | 2010-05-14 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
| EP2593475B1 (en) * | 2010-07-14 | 2016-03-02 | Merck Sharp & Dohme Corp. | Anti-addl monoclonal antibody and uses thereof |
| EP2906597B1 (en) * | 2012-10-15 | 2020-04-08 | Medimmune Limited | Antibodies to amyloid beta |
-
2020
- 2020-07-15 CN CN202511495657.4A patent/CN121800915A/zh active Pending
- 2020-07-15 WO PCT/US2020/042161 patent/WO2021011673A2/en not_active Ceased
- 2020-07-15 EP EP20750124.8A patent/EP3999532A2/en active Pending
- 2020-07-15 KR KR1020227004730A patent/KR20220034857A/ko active Pending
- 2020-07-15 JP JP2022502422A patent/JP7685985B2/ja active Active
- 2020-07-15 CN CN202080063538.0A patent/CN115175932B/zh active Active
- 2020-07-15 CN CN202511495659.3A patent/CN121949538A/zh active Pending
- 2020-07-15 CA CA3147239A patent/CA3147239A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2421464C2 (ru) | Человеческие антитела к il-13 и их терапевтическое применение | |
| JP2018510617A5 (enExample) | ||
| RU2012107286A (ru) | Высокоаффинные человеческие антитела к человеческому ангиопоэтину-2 | |
| RU2012156938A (ru) | Антитела против gdf8 человека | |
| JP2018527919A5 (enExample) | ||
| RU2014113046A (ru) | Профилактика и лечение патологических состояний глаз, вызванных комплементом | |
| JP2015514110A5 (enExample) | ||
| RU2019134352A (ru) | Новые биспецифические антигенсвязывающие молекулы, обладающие способностью специфически связываться с cd40 и fap | |
| JP2020513791A5 (enExample) | ||
| JP2020513786A5 (enExample) | ||
| RU2009133789A (ru) | Способы лечения глазных болезней | |
| JP2009530423A5 (enExample) | ||
| JP2010528047A5 (enExample) | ||
| JP2018506277A5 (enExample) | ||
| JP2014502955A5 (enExample) | ||
| CA2501984A1 (en) | Erythropoietin receptor binding antibodies | |
| JP2015509948A5 (enExample) | ||
| FI973120A0 (fi) | Ihmisen gp39:n eri epitoopeille spesifisiä monoklonaalisia vasta-aineita ja menetelmiä niiden käyttämiseksi diagnosoinnissa ja terapiassa | |
| JP2021523100A5 (enExample) | ||
| JP2018529661A5 (enExample) | ||
| JP2021518761A5 (enExample) | ||
| JP2021510523A5 (enExample) | ||
| JP2021520393A5 (enExample) | ||
| JP2022513331A5 (enExample) | ||
| JP2022515152A5 (enExample) |